← Leaderboards
Anushka Naidoo
Centre/Aids Programme/Res/South Africa
$2,043,607
Attributed
$3,471,119
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–24$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,471,119 · 2
By mechanism
R01$2,855,024 · 1
K43$616,095 · 1
Top collaborators
- Kelly E. Dooley10 shared
Most similar at Centre/Aids Programme/Res/South Africa
Same institution · by research overlap
- Quarraisha Abdool Karim$35,100,516
- Nigel Joel Garrett$2,048,987
Others in their field
Other Emerging Leaders on “Tuberculosis”
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$72,037,072
- Yunda Huang · Fred Hutchinson Cancer Center$52,438,893
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$31,845,607
- Jay Evans · University Of Montana$15,453,274
Research focus
TuberculosisTreatment ProtocolsProtease InhibitorPositioning AttributeSouth AfricaSamplingHiv/TbExposure ToIntegrasePlasmaRegimenEfavirenzResistanceRifampinDrug KineticsCo-InfectionEnrollmentCyp3a4 GeneDoseEnzymesDrug InteractionsPharmaceutical PreparationsAntiretroviral TherapyTuberculosis Drugs
Grant awards (16)
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$290,914
R01 · FY2024 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$285,787
R01 · FY2024 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$282,070
R01 · FY2024 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$200,932
R01 · FY2024 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$369,940
R01 · FY2023 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$303,515
R01 · FY2023 · AI · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$129,848
R01 · FY2023 · AI · contact PI
Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa$112,056
K43 · FY2023 · TW · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$315,411
R01 · FY2022 · AI · contact PI
Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa$107,826
K43 · FY2022 · TW · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$330,027
R01 · FY2021 · AI · contact PI
Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa$107,300
K43 · FY2021 · TW · contact PI
Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa$81,000
K43 · FY2021 · TW · contact PI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa$346,580
R01 · FY2020 · AI · contact PI
Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa$105,079
K43 · FY2020 · TW · contact PI
Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa$102,834
K43 · FY2019 · TW · contact PI